Rachel Klamo, DO
Family Medicine · Oxford, MINPI 1497953533
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,443 of the $19,346 with a category attached, or 90.2%. 20 manufacturers reported payments, led by Organon at 58.6% of the total. Reporting peaked in 2022 at $5,631 and has fallen 98.1% since, to $109 in 2025. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 95 payments — averaging $203.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$11K
- Merck$6K
- Amgen$408
- Novo Nordisk$281
- Boston Scientific$149
- Astellas Pharma US Inc$129
- plus $613 from 14 others
What the payments were for
- Speaking & faculty fees$17,44390%
- Travel & lodging$1471%
- Food & beverage$1,7569%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 16 | $11,346 |
| Merck | 14 | $6,420 |
| Amgen | 14 | $408 |
| Novo Nordisk | 16 | $281 |
| Boston Scientific | 1 | $149 |
| Astellas Pharma US Inc | 2 | $129 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $103 |
| Biotronik Inc. | 1 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $86 |
| Teva Pharmaceuticals USA, Inc. | 5 | $85 |
| GSK | 3 | $52 |
| AbbVie | 2 | $34 |
| Zyla Life Sciences, Inc. | 2 | $26 |
| Amarin Pharma, Inc. | 2 | $24 |
| Pfizer | 2 | $24 |
| Genentech USA, Inc. | 1 | $21 |
| Medtronic | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Edwards Lifesciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,346 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $64,845 |
| EliquisApixaban | 21 | $21,219 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,350 |
| Estradiol | 24 | $2,144 |
| Levothyroxine Sodium | 127 | $1,869 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $1,708 |
| Estradiol (Twice Weekly)Estradiol | 17 | $1,499 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,312 |
| Atorvastatin Calcium | 124 | $1,276 |
| Omeprazole | 67 | $1,264 |
| Losartan Potassium | 86 | $1,153 |
| Lisinopril | 108 | $967 |
| Rosuvastatin Calcium | 60 | $946 |
| Metoprolol Succinate | 42 | $916 |
| Sertraline Hcl | 37 | $840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $281 | $64,84544 claims |
| PfizerEliquis | $24 | $21,21921 claims |
| AbbVieSynthroid | $34 | $58614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Oxford
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.